Director converts AIDX Series A-2 preferred into common on Nasdaq listing

Rhea-AI Filing Summary

20/20 Biolabs, Inc. director Michael A. Ross reported an automatic conversion of preferred stock into common stock tied to the company’s listing on the Nasdaq Capital Market. On February 19, 2026, all 31 shares of Series A-2 preferred stock he held converted into 31 shares of common stock at no stated cost, leaving him with 31 common shares held directly and no remaining Series A-2 preferred shares.

Insights

Equity compensation and governance analyst

Director’s preferred shares automatically converted to common upon Nasdaq listing.

The filing shows Michael A. Ross, a director of 20/20 Biolabs, Inc., had 31 shares of Series A-2 preferred stock automatically convert into 31 common shares on February 19, 2026. The transaction price per share is reported as $0.0000, indicating a non-cash conversion.

This was triggered by the listing of the company’s common stock on the Nasdaq Capital Market, as described in the footnote. After the conversion, the director directly holds 31 common shares and no Series A-2 preferred shares. This is a routine capitalization and listing-related clean-up rather than an open-market purchase or sale, so the impact on investors is neutral.

Insider Trade Summary

31 shares exercised/converted

Mixed 2 txns

Insider Ross Michael A.

Role Director

Type	Security	Shares	Price	Value
Conversion	Series A-2 Preferred Stock	31	$0.00	--
Conversion	Common Stock	31	$0.00	--

Holdings After Transaction: Series A-2 Preferred Stock — 0 shares (Direct); Common Stock — 31 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/23/2026 - 06:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Michael A.

(Last) (First) (Middle)

C/O 20/20 BIOLABS, INC.

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG MD 20877

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		C(1)		31	A	$0	31	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-2 Preferred Stock(1)	(1)	02/19/2026		C(1)			31	(1)	(1)	Common Stock	31	(1)	0	D

Explanation of Responses:

1. On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.

	/s/ Michael A. Ross	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 20/20 Biolabs (AIDX) report for Michael A. Ross?

20/20 Biolabs reported that director Michael A. Ross converted 31 Series A-2 preferred shares into 31 common shares. The conversion occurred on February 19, 2026, was non-cash at a stated price of $0.0000 per share, and left him holding 31 common shares directly.

Was the AIDX insider transaction a buy or sell of common stock?

The AIDX insider transaction was an acquisition of common stock through derivative conversion, not an open-market buy or sell. Series A-2 preferred shares automatically converted into an equal number of common shares based on preset terms tied to the company’s Nasdaq Capital Market listing.

How many AIDX shares does director Michael A. Ross own after the conversion?

After the reported transaction, director Michael A. Ross holds 31 shares of AIDX common stock directly. All 31 of his Series A-2 preferred shares were converted into 31 common shares, leaving him with no remaining Series A-2 preferred stock according to the Form 4 totals.

What triggered the conversion of AIDX Series A-2 preferred stock into common stock?

The conversion of AIDX Series A-2 preferred stock was automatically triggered by the listing of 20/20 Biolabs’ common stock on the Nasdaq Capital Market. Upon this listing event, all Series A-2 preferred shares held by the reporting person converted into an equal number of common shares under their terms.

Did the AIDX insider pay cash for the newly acquired common shares?

No cash was paid for the newly acquired AIDX common shares in this transaction. The Form 4 reports a transaction price of $0.0000 per share, indicating a purely derivative conversion of 31 Series A-2 preferred shares into 31 common shares without a separate cash purchase.

Did the AIDX Series A-2 preferred stock have an expiration date before conversion?

The AIDX Series A-2 preferred stock held by the reporting person had no expiration date before conversion. The footnote explicitly states that the Series A-2 preferred stock had no expiration date, and all held shares converted automatically into common stock upon the Nasdaq Capital Market listing.